Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 13/20 | 0.64 |
| ▸ | TPO | P07202 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | EPX | P11678 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | FABP6 | P51161 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18618932 | 0.91 | MPO (0.65) | MPOTPOCYP3A4EPXABL1 | |
| SCHEMBL18617439 | 0.86 | MPO (0.56) | MPOTPOCYP3A4EPX | |
| SCHEMBL18586508 | 0.86 | MPO (0.56) | MPOTPOCYP3A4EPX | |
| SCHEMBL20515423 | 0.84 | MPO (0.60) | MPOTPOCYP3A4EPXKLKB1 | |
| SCHEMBL18620306 | 0.82 | MPO (0.60) | MPOTPOCYP3A4EPX | |
| SCHEMBL18621239 | 0.79 | MPO (0.60) | MPOTPOCYP3A4EPX | |
| SCHEMBL18586867 | 0.79 | MPO (0.70) | MPOHDAC6 | |
| SCHEMBL20515418 | 0.79 | MPO (0.44) | MPOTPOCYP3A4EPX | |
| SCHEMBL20515410 | 0.79 | MPO (0.58) | MPOTPOCYP3A4EPX | |
| SCHEMBL18620122 | 0.79 | MPO (0.67) | MPODHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180282320-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2017040451-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282320-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | MPO 2/4885TPO 7/4885CYP3A4 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.